Skip to main content

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

Completed · Phase 2 · NCT06055985

Conditions: Parkinson Disease

At a glance

Research payments reported, 2025
$2.4M
U.S. investigators named
65
Sites paid
64
Planned or actual enrollment
207

About the trial

Sponsor
UCB Biopharma SRL
Tested
Placebo (other), UCB0022 (drug)
Dates
Started 2023-11-17; completion 2025-04-11
Results posted
Not yet

The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson's Disease (PD).

From ClinicalTrials.gov, last updated 2026-04-06. Full record, eligibility and contacts (opens in a new tab)

Industry funding

UCB SA reported $2.4M in research payments for this study in 2025 (68 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.